Advancing cell therapy for neurodegenerative diseases

Cell stem cell, Journal Year: 2023, Volume and Issue: 30(5), P. 512 - 529

Published: April 20, 2023

Language: Английский

---

The schizophrenia syndrome, circa 2024: What we know and how that informs its nature

Schizophrenia Research, Journal Year: 2023, Volume and Issue: 264, P. 1 - 28

Published: Dec. 12, 2023

Language: Английский

---

Biological hypotheses, risk factors, and biomarkers of schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry, Journal Year: 2022, Volume and Issue: 120, P. 110626 - 110626

Published: Aug. 31, 2022

Language: Английский

---

Clinical anatomy of the precuneus and pathogenesis of the schizophrenia

Anatomical Science International, Journal Year: 2023, Volume and Issue: 98(4), P. 473 - 481

Published: June 20, 2023

Language: Английский

---

The magnitude and variability of neurocognitive performance in first-episode psychosis: a systematic review and meta-analysis of longitudinal studies

Translational Psychiatry, Journal Year: 2024, Volume and Issue: 14(1)

Published: Jan. 8, 2024

Abstract Neurocognitive deficits are a core feature of psychotic disorders, but it is unclear whether they affect all individuals uniformly. The aim this systematic review and meta-analysis was to synthesize the evidence on magnitude, progression, variability neurocognitive functioning in with first-episode psychosis (FEP). A multistep literature search conducted several databases up November 1, 2022. Original studies reporting FEP were included. researchers extracted data clustered tasks according seven Measurement Treatment Research Improve Cognition Schizophrenia (MATRICS) domains six additional domains. Random-effect model meta-analyses, assessment publication biases study quality, meta-regressions conducted. primary effect size reported Hedges g (1) at measuring differences healthy control (HC) or (2) evolution impairment across follow-up intervals. Of 30,384 screened, 54 included, comprising 3,925 1,285 HC individuals. Variability analyses indicated greater compared baseline follow-up. We found better performance group no longitudinal changes between groups. Across 13 domains, showed improvement from studied except for visual memory. Metaregressions some findings suggest that have marked cognitive impairment, there patients than HC. This suggests subgroups suffer severe disease-related impairments, whereas others may be much less affected. While these impairments seem stable medium term, certain indicators potential further decline long term specific subgroup individuals, although more research needed clarify this. Overall, highlights need tailored interventions based their progression.

Language: Английский

---

What Is Mental Effort: A Clinical Perspective

Biological Psychiatry, Journal Year: 2024, Volume and Issue: 95(11), P. 1030 - 1037

Published: Feb. 1, 2024

Although mental effort is a frequently used term, it poorly defined and understood. Consequently, its usage loose potentially misleading. In neuroscience research, the term to mean both cognitive 'work' that done in meeting task demands, subjective experience of performing work. We argue conflating these two meanings hampers progress understanding impairments neuropsychiatric conditions, because work have distinct underlying mechanisms. suggest most coherent clinically useful perspective on experience. This makes clear distinction between arising from changes apparatus, as dementia brain injury, those difficulties carrying out work, attention deficit hyperactivity disorder, depression, other motivational disorders. review recent advances suggesting has emerged control switches so minimise 'costs' relative 'benefits.' consider how can contribute our increased perception clinical populations. more specific framing will offer deeper mechanisms differing groups, ultimately facilitate better therapeutic interventions.

Language: Английский

---

Neuroinflammatory Loop in Schizophrenia, Is There a Relationship with Symptoms or Cognition Decline?

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(1), P. 310 - 310

Published: Jan. 1, 2025

Schizophrenia (SZ), a complex psychiatric disorder of neurodevelopment, is characterised by range symptoms, including hallucinations, delusions, social isolation and cognitive deterioration. One the hypotheses that underlie SZ related to inflammatory events which could be partly responsible for symptoms. However, it unknown how molecules can contribute decline in SZ. This review summarises exposes possible contribution imbalance between pro-inflammatory anti-inflammatory interleukins like IL-1beta, IL-4 TNFalfa among others on impairment. We discuss this affects microglia astrocytes inducing disruption blood–brain barrier (BBB) SZ, impact prefrontal cortex or associative areas involved executive functions such as planning working tasks. also highlight generated intestinal microbiota alterations, due dysfunctional microbial colonisers use some anti-psychotics, central nervous system. Finally, question arises whether modulate correct characterises if an immunomodulatory strategy incorporated into conventional clinical treatments, either alone complement, applied specific phases, prodromal first-episode psychosis.

Language: Английский

---

Schizophrenia: A developmental disorder with a risk of non-specific but avoidable decline

Schizophrenia Research, Journal Year: 2022, Volume and Issue: 243, P. 181 - 186

Published: April 4, 2022

Language: Английский

---

Psychosis superspectrum I: Nosology, etiology, and lifespan development

Molecular Psychiatry, Journal Year: 2024, Volume and Issue: 29(4), P. 1005 - 1019

Published: Jan. 10, 2024

Language: Английский

---

Use of the Chinese version of the MATRICS Consensus Cognitive Battery to assess cognitive functioning in individuals with high risk for psychosis, first-episode schizophrenia and chronic schizophrenia: a systematic review and meta-analysis

The Lancet Regional Health - Western Pacific, Journal Year: 2024, Volume and Issue: 45, P. 101016 - 101016

Published: Feb. 9, 2024

More than one hundred studies have used the mainland Chinese version of MATRICS Consensus Cognitive Battery (MCCB) to assess cognition in schizophrenia, but results these studies, quality reports, and strength evidence provided reports not been systematically assessed. We identified 114 from English-language Chinese-language databases that MCCB combined samples 7394 healthy controls (HC), 392 individuals with clinical high risk for psychosis (CHR-P), 4922 first-episode schizophrenia (FES), 1549 chronic (CS), 2925 unspecified duration. The mean difference (MD) composite T-score (−13.72) T-scores each seven cognitive domains assessed by (−14.27 −7.92) were significantly lower controls. Meta-analysis greater impairment FES CS CHR-P six reasoning problem-solving domain (i.e., executive functioning). only significant covariate overall functioning was a negative association severity psychotic symptoms. These confirm construct validity MCCB. However, there limitations about (small pooled sample sizes) social (inconsistency across studies), many (particularly those published Chinese) rated 'poor' due failure report size calculations, matching procedures or methods handling missing data. Moreover, almost all cross-sectional limited persons under 60 at least nine years education, so longitudinal under-educated, older are needed.

Language: Английский

---